• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Nimbolide inhibits tumor growth by restoring hepatic tight junction protein expression and reduced inflammation in an experimental hepatocarcinogenesis

    2021-01-15 09:01:28AmitKumarRamBalasubramaniyanVairappanBHSrinivas
    World Journal of Gastroenterology 2020年45期

    Amit Kumar Ram, Balasubramaniyan Vairappan, BH Srinivas

    Abstract

    Key Words: Hepatocellular carcinoma; Nimbolide; Tight junction; Inflammation; Oxidative stress; Zonula occludens 1 associated nucleic acid binding protein

    INTRODUCTION

    Hepatocellular carcinoma (HCC) is one of the most lethal malignancies and ranks third in the annual cancer mortality rate with overall 6-20 months of median survival after diagnosis[1]. The etiological factors such as hepatitis viral infection and alcohol abuse instigate chronic inflammation in the liver and lead to cirrhosis and ultimately HCC at the terminal stage[2]. The treatment modalities for HCC are limited with surgical resection and liver transplantation. The frequency of recurrence of HCC is high[1]. Since most of the HCC patients are diagnosed in an advanced stage, surgical options are unsuitable and only systemic chemotherapy (doxorubicin or sorafenib) and supportive care are the best available treatment options, however, only minimally increase the lifespan. Moreover, chemotherapy has low efficiency and side effects, and do not improve the 5-year survival rates[3]. Besides, due to the development of drug resistance and the existence of genetic heterogeneity within the individuals, the clinical outcome of targeted therapies is less effective[4]. Therefore, the discovery and development of successful new molecular chemotherapeutic agents targeting multiple pathways simultaneously are an immediate need to prevent the disease progression and recurrence in HCC patients.

    Tight junction (TJ) proteins are intercellular adhesion molecules located at the apical and basolateral membrane and play a fundamental role in maintaining tissue barrier and cellular integrity[5]. It regulates paracellular movement in endothelial cells, whereas in epithelial cells it tightly seals the gap between adjacent cells in an adhesive manner and prevents cell dissociation[6]. Of note, HCC is a type of epithelial cell carcinoma[7]. In the liver, TJ proteins are present in the hepatocytes and biliary epithelial cells, which form a blood-biliary barrier[8]. Zonula occludens (ZO)-1, a membrane-associated scaffolding protein that belongs to membrane associated guanylate kinase family, contains three PDZ domains, a single SH3 domain and a GK domain[9]. ZO-1 binds to occludin (transmembrane protein)viaits GK domain and interacts with homologous family members ZO-2 and ZO-3viathe second PDZ domain[10,11]. Apart from barrier function, TJs proteins have been implicated in cellular signal transduction to modulate cell proliferation and differentiation[12]. It has been found that SH3 domain of ZO-1 shares homology with SH3 domain of lethal disc large-1 tumor suppressor gene of drosophila, and its deletion or mutation leads to cell overgrowth and neoplastic changes, suggesting ZO-1 acts as a tumor suppressor[13]. ZO-1 binds to Y-box transcription factor ZO-1 associated nucleic acid binding protein (ZONAB), which interacts with the cell cycle kinase cyclin dependent kinase (CDK4), and regulates transcription of cell cycle related genes such as proliferating cell nuclear antigen (PCNA) and CyclinD1, providing a molecular link between ZO-1 and ZONAB, thereby regulating cellular proliferation[14,15]. Alteration in TJ proteins leads to a decrease in cell-cell adhesion, which is a crucial step to the cellular phenotypic transformation for tumor initiation and progression. Indeed, loss of TJ proteins such as ZO-1, occludin, and claudin have been shown to correlate with increased invasiveness, metastasis, and poor prognosis in breast cancer and colorectal cancer[16-18]. Similarly, although occludin-/-mice exhibited no gross anatomical defects, the gastric epithelial cells became hyperplastic after 40 wk[19]. Of note, our human study in HCC patients indicated a significant correlation between hepatic ZO-1 and high-sensitive C-reactive protein, however, the causal relationship remains unclear[20].

    Nimbolide is a tetranotriterpenoid, and an active compound isolated from leaves and flowers of the Neem tree (Azadirachta indica), which is a traditional medicinal plant of Meliaceae family which is widely distributed in Asia, Africa, and other tropical parts of the world[21]. Several published studies have shown evidence that nimbolide induces apoptosis, inhibits cell proliferation, and metastasis in a variety of cancer cells including prostate, breast cancer, and choriocarcinoma cell lines[22-24]. Furthermore, the antitumor activities of nimbolide have been shown to have beneficial effects in preclinical models of various cancers such as oral squamous cell carcinoma[25], prostate cancer, and pancreatic cancer[26,27]. Nimbolide also induces cell cycle arrest and apoptosis in renal cell carcinoma[28]and its antioxidant and anti-inflammatory activities were widely studied usingin vivoandin vitromodels[29,30]. In the current study, we aimed to investigate the effect of nimbolide on TJ protein expression, cell cycle progression, and inflammation in diethylnitrosamine (DEN) and N-nitrosomorpholine (NMOR) induced experimental HCC in mice.

    MATERIALS AND METHODS

    Materials

    DEN (N0756) and NMOR (N7382) were purchased from Sigma-Aldrich, St. Louis, Missouri, United States. Nimbolide of 97% purity (AHRF/NP/001) was procured from Asthagiri Herbal Research Foundation, Chennai, Tamilnadu, India. Doxorubicin hydrochloride (10 mg vial, Biochem pharmaceutical industries Ltd., Mumbai, India) was obtained from the Department of Medical Oncology, JIPMER.

    Animals and treatment procedure

    Male Swiss mice (CD-1 strain) weighing 10-15 g were obtained from the central animal facility, JIPMER, and maintained in a specific pathogen-free environment. All the animals were housed in polypropylene cages and maintained at 21-25 °C with 12 h light/dark cycle and free (ad libitum) access to water and standard rodent pellets. All experimental study was approved by JIPMER Institute Animal Ethics Committee and was carried out in accordance with the Committee for the Purpose of Control and Supervision of Experiments in Animals (CPCSEA) guidelines.

    Induction of HCC:Hepatocellular carcinoma was induced in mice by administering a single intraperitoneal (i.p.) injection of DEN [100 mg/kg body weight in phosphate buffer saline (PBS)] and subsequent administration of NMOR in the drinking water (80 ppm) for 28 wk. After tumor formation at 28thweek, the mice were randomized into five groups. Group I Naive mice continued to receive standard pellet diet and waterad libitumfor four weeks. Group II na?ve + treatment mice continued to receive standard pellet diet and waterad libitum, and were administered with nimbolide (6 mg/kg body weight in PBS) daily for four weeks through oral gavage. Group III HCC mice continued to receive standard pellet diet and waterad libitum, and were administered PBS (oral) for four weeks. Group IV HCC mice were administered with nimbolide (6 mg/kg body weight in PBS) daily for four weeks through oral gavage. Group V HCC mice were treated with the standard anticancer drug doxorubicin hydrochloride (1 mg/kg body weight in saline; i.p.) weekly thrice for the next four weeks to compare the chemotherapeutic efficacy of nimbolide. The final study groups were: (1) Na?ve (n= 8); (2) Na?ve + nimbolide (n= 8); (3) HCC (n= 10); (4) HCC + nimbolide (n= 10); and (5) HCC + doxorubicin (n= 10). The experimental protocol and treatment schedule is depicted in Figure 1A.

    At termination (end of 32ndweek) mice in different study groups were sacrificed by exsanguination under anaesthesia (ketamine hydrochloride 100 mg/kg). Blood was collected from the cardiac puncture in a heparinized tube, centrifuged at 3500 rpm at 4 °C for 10 min; plasma separated was stored at -80 °C for further analysis. After weighing liver tissues, parts of hepatic tumor nodules were excised, washed with PBS, and stored in 10% neutral buffered formalin for histopathological analysis, and the remaining liver tissue/nodules were snap-frozen in liquid nitrogen and stored in-80 °C for molecular studies.

    Morphological and histological assessment of liver tumor

    The entire visible and macroscopic nodules on the surface of the liver were counted for each mouse in all experimental groups. The length (L) and width (W) of superficial tumor nodules were measured by using a digital vernier caliper. The largest length (L) of the nodule was considered as the maximum tumor diameter. The volume of the tumor was calculated using the formula; volume (V) = L × (W)2/2. Tumor burden was calculated by multiplying mean tumor volume with the no. of nodules for each mouse in the experimental groups. Percentage tumor growth inhibition (% TGI) was defined as the difference between mean tumor volume (MTV) of DEN + NMOR treated (MTVD) and chemotherapeutic group (MTVT) at 32ndweek, using the formula: % TGI = [(MTVD - MTVT)/MTVD] × 100.

    For histopathological analysis, 10% formalin-fixed liver tissues were dehydrated with a series of graded alcohol, cleared in xylene, and embedded in paraffin wax. Thereafter, 5 μm tissue sections were cut and stained with hematoxylin and eosin (HE) with standard protocol. HE stained sections were assessed for histological features of HCC by an independent pathologist in a blind fashion. Numbers of mitotic cells in 10 high-power fields (HPF, 400 ×) were counted on HE stained slides and the highest number of mitotic cells among them was defined as the mitotic index.

    Analysis of liver function parameters and alpha-fetoprotein

    Plasma liver function parameters such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were measured by autoanalyzer using Beckman coulter kits (United States), according to manufacturer instruction. HCC tumor marker alpha-fetoprotein (AFP) was measured in plasma by ELISA kit (CKbio-15638; Shanghai, China).

    Western blotting

    Figure 1 Effect of nimbolide on body weight and liver coefficient in diethylnitrosamine and N-nitrosomorpholine induced hepatocellular carcinoma mice. A: Flowchart for the experimental hepatocarcinogenesis model; B: Average weekly body weight of na?ve and experimental mice; C: Liver coefficient of na?ve and experimental mice. All the data are expressed as mean ± SEM (n = 6-10). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison test post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. cP < 0.0001 compared to na?ve group; fP < 0.001 compared to hepatocellular carcinoma group. DEN: Diethylnitrosamine; HCC: Hepatocellular carcinoma; NMOR: N-nitrosomorpholine; PBS: Phosphate buffer saline.

    Liver tissues were snap-frozen in liquid nitrogen and stored at -80 °C for western blot analysis. About 150 mg of tissue was weighed and homogenized in 500 μL ice-cold RIPA buffer (G-Biosciences, St. Louis, MO, United States) with protease inhibitor cocktail (P8340, Sigma-Aldrich, St. Louis, MO, United States) and 10% protein methyl sulfonyl fluoride (in ethanol). Tissue homogenate was centrifuged at 14000 g for 10 min at 4 °C and supernatant was collected. The protein content of the individual sample was estimated by Bradford assay using the Pierce coomassie protein assay kit (23200, Thermo Fisher Scientific, Rockford, IL, United States). About 30 μg of total protein of individual sample was diluted in SDS sample buffer and were resolved using SDS-polyacrylamide gel electrophoresis and blotted onto a nitrocellulose membrane (S045A330R, Advantec, Tokyo, Japan). Then the membranes were blocked for non-specific binding with 5% non-fat dry milk (GRM1254; Himedia, Mumbai, India) in Tris-buffered saline containing 0.01% Tween 20 (TBST) for 1 h at room temperature, followed by overnight incubation with primary antibody at 4 °C. The primary antibodies used were rabbit polyclonal anti-ZO1 (1:1000, 61-7300; Thermo Fisher, Rockford, IL, United States), rabbit polyclonal anti-ZONAB (1:500, 40-2800; Thermo Fisher, Rockford, IL, United States), mouse monoclonal anti-occludin (1:1000, sc-133256; Santa Cruz, Dallas, TX, United States), rabbit polyclonal anti-CDK4 (1:1000, A0366; Abclonal, Woburn, Massachusetts, United States), rabbit polyclonal anti-CyclinD1 (1:1000, A2708; Abclonal, Woburn, MA, United States), rabbit monoclonal anti-nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB)p65 (1:1000, 8242S; CST, Danvers, MA, United States), rabbit polyclonal anti-tumor necrosis factor alpha (TNF-α) (1:1000, 2081R; BIOSS, Woburn, Massachusetts, United States), rabbit polyclonal anti-Interleukin 1 beta (IL-1β) (1:1000, A11370; Abclonal, Woburn, MA, United States) and mouse monoclonal anti-β-actin (1:1000, AC004; Abclonal, Woburn, MA, United States). After overnight incubation, membranes were washed with TBST three times and incubated with peroxidase-conjugated goat antirabbit (1:10000, 406401; BioLegend, San Diego, CA, United States) or goat anti-mouse (1:10000, 405306; BioLegend, San Diego, CA, United States) for 1 h at room temperature and the bands were visualized using an enhanced chemiluminescent substrate (34087; West pico detection kit, Thermo Scientific, Rockford, IL, United States) in Chemidoc system (Bio-rad, United States). Protein bands were quantified using Image Lab software (Bio-rad, United States).

    Immunohistochemistry

    3-5 μm thick sections were cut using an automated microtome (Leica Biosystems) and mounted on a silane coated slide. After deparaffinization, slides were immersed in xylene and rehydrated in different graded ethanol followed by 3% H2O2in methanol for 15 min to quench the endogenous peroxidase activity. Then the sections were rinsed with PBS, and antigen retrieval was performed using citrate buffer (PH = 6.0) in the decloaking system at 110°C for 10 min. After blocking, the sections were incubated with primary antibody overnight at 4°C. Primary antibodies used were rabbit polyclonal anti-glypican-3 (1:100, A13988; Abclonal, Woburn, MA, United States), rabbit polyclonal anti-PCNA (1:100, A0264; Abclonal, Woburn, MA, United States), and rabbit polyclonal anti-4-Hydroxynonenal (4HNE) (1:100, bs-6313R; Bioss, Woburn, Massachusetts, United States). After washing with PBS, sections were incubated with universal anti-mouse/rabbit Ig (MP-7500; Vector lab, Burlingame, CA, United States) for 30 min at room temperature and immunostaining was performed with ImmPACT DAB kit (SK4105; Vector lab, Burlingame, CA, United States) and counterstained with hematoxylin. After mounting with Histamount solution, sectioned were examined under EVOS FLc imaging system (Life Techonologies, United States).

    Molecular docking analysis

    Molecular docking using Schodinger AutoDock 4.0 software (United States) was performed to predict the binding affinity of nimbolide with ZO-1, NF-κB, and TNF-α. The X-ray crystal structure of ZO-1 [Protein Data Bank archive (PDB) ID: 2RRM], NFκB (PDB ID: 1VKX), and TNF-α (PDB ID: 2TNF) were retrieved from RCSB protein data bank (http://www.rcsb.org). The proteins were prepared before molecular docking using PyMol software (Schrodinger LLC, Cambridge, United States). Nimbolide (CID: 100017) 2D structure was retrieved from the Pubchem database (https://pubchem.ncbi.nlm.nih.gov/compound) in SDF file format and then converted to .mol2 format using Open Babel software version 2.4.1. After the simulation, different docked conformations were obtained and conformation with the strongest binding affinity towards ligand binding cavity of ZO-1, NF-κB, and TNF-α were selected as possible binding conformations and taken for further analysis. The final assessment of protein-ligand interaction was done and interpreted as Glide score (kcal/moL).

    Statistical analysis

    All the data are expressed as mean ± standard error of mean (SEM). Results were analyzed using GraphPad Prism 6.0 software. The comparison between different groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or by Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. AP< 0.05 was considered as statistical significance.

    RESULTS

    Effect of nimbolide on body weight, liver weight and liver coefficient in DEN/NMOR induced HCC mice

    Experimental mice were treated with nimbolide or doxorubicin (Figure 1A) and the average weekly bodyweight of the naive and experimental mice was represented in Figure 1B. HCC induction in mice showed a decreased bodyweight throughout the experimental period compared to naive mice. Nimbolide or doxorubicin treatment to HCC mice showed a trend in increased body weight from 28thto 32ndweek (P= 0.6781) (Figure 1B). Furthermore, the liver/body weight ratio measured was higher (P< 0.0001) in HCC mice compared to na?ve mice and this may be due to the induction of tumors by DEN and NMOR. On the contrary, treatment with nimbolide to HCC mice showed reduced liver/body weight ratio (P< 0.001) when compared to DEN/NMOR induced HCC mice, suggesting nimbolide possibly alleviated tumor burden (Figure 1C). Similar effects were seen in mice treated with doxorubicin in DEN/NMOR induced HCC mice (Figure 1C). Na?ve mice treated with nimbolide shows similar body weight and liver/body weight ratio when compared to the na?ve mice alone group.

    Nimbolide inhibits DEN/NMOR induced hepatocarcinogenesis

    Macroscopically visible hepatic nodules were evident on the liver surface of HCC mice, whereas, treatment with nimbolide or doxorubicin showed much lesser hepatic nodules (Figure 2A). Moreover, the maximum tumor diameter measured was higher in HCC mice and was reduced following treatment with nimbolide (P< 0.05) or doxorubicin (P< 0.05) to HCC mice (Figure 2B). The calculated tumor burden was also higher in HCC mice. Treatment with nimbolide (P< 0.05) or doxorubicin (P< 0.05) to HCC mice showed reduced tumor burden compared to HCC mice alone group (Figure 2C). Also, nimbolide or doxorubicin treatment to HCC mice inhibited tumor growth by 52.08% and 54.45%, respectively, with the reduction in mean tumor volume (P< 0.01) compared to HCC mice alone group (Table 1).

    To identify the effective dose of nimbolide, we performed a dose-response study with three different doses of nimbolide (1.5 mg/kg, 3 mg/kg, and 6 mg/kg body weight) in DEN/NMOR induced HCC mice. We found treatment with 6 mg/kg nimbolide reduced maximum tumor diameter (P< 0.05) (Supplementary Figure 1) and tumor volume (P< 0.05) (Supplementary Figure 2) in HCC mice, while 1.5 mg/kg and 3 mg/kg nimbolide treatment were not significant compared to HCC mice alone group. Liver function parameters and AFP levels were also significantly decreased to HCC mice following 6 mg/kg b.w. nimbolide treatment (Supplementary Table 1). Based on the above preliminary data, the effective dose of 6 mg/kg b.w. nimbolide was chosen for subsequent experiments.

    To confirm the malignancy potential of DEN/NMOR induced hepatocarcinogenesis, representative hematoxylin and eosin stained sections of the liver was studied and the results were shown in Figure 2D. Naive (Figure 2D, panel a) and na?ve + nimbolide (Figure 2D, panel b) mice liver showed normal hepatic lobular architecture whereas, HCC mice liver showed neoplastic changes (Figure 2D, panel c). The neoplastic changes in the liver showed classical features of HCC characterized by hepatocyte arranged in cords (3 cell layer), cellular atypia, eosinophilic to clear cytoplasm, enlarged nucleus, and hyperchromasia. Treatment with nimbolide or doxorubicin showed minimal cellular atypia and decreased nuclear: Cytoplasmic ratio (Figure 2D, panel d and e). Furthermore, the mitotic index is a simple method for the evaluation of cellular proliferation rate and is a hallmark feature of cancer. Indeed, the mitotic index is a predictor of prognosis in patients with HCC[31]. Hematoxylin and eosin stained liver section of HCC mice showed a higher mitotic index (3-4/10 HPF) whereas, a lower mitotic index (1-2/10 HPF) was observed in nimbolide or doxorubicin treated HCC mice liver (Table 2).

    Effect of nimbolide on liver function parameters and tumor and cell proliferation markers in DEN/NMOR induced HCC mice

    Elevated levels of hepatic dysfunction marker enzymes such as AST, ALT, and ALP are widely used to assess hepatic dysfunction, and are associated with HCC progression[32]. DEN/NMOR induced HCC mice showed elevated levels of AST, ALT, and ALP (P< 0.0001) when compared to naive mice. Treatment with nimbolide or doxorubicin to HCC mice lowered the plasma levels of AST, ALT, and ALP (P< 0.01) compared to HCC mice alone group (Figure 3A-C). Plasma alpha-fetoprotein (AFP) levels and glypican-3 are clinically used as tumor markers for the diagnosis and prognosis of HCC[33,34]. Reduced AFP levels was reported to have prognostic significance after hepatic tumor resection and transarterial chemoembolization in HCC patients[35,36]. We found a higher plasma AFP levels in HCC mice (P< 0.0001) compared to naive mice. Nimbolide or doxorubicin treatment to HCC mice showed decreased plasma AFP levels (P< 0.01) compared to HCC mice alone group (Figure 3D). Increased hepatic glypican-3 expression was associated with a significantly lower 5-year survival rate and poor prognosis in HCC patients[34]. Figure 3E shows the immunostaining of glypican-3 on the liver sections of naive and experimental mice.Naive mice (Figure 3E, panel a) and na?ve + nimbolide mice (Figure 3E, panel b) liver showed negative reactivity to glypican-3 whereas, strong glypican-3 cytoplasmic positivity was seen in HCC mice liver (Figure 3E, panel c), while nimbolide or doxorubicin treatment to HCC mice showed reduced glypican-3 cytoplasmic positivity (Figure 3E, panel d and e). Quantification of glypican-3 positive cells in the experimental group was represented in Figure 3F. PCNA is a putative marker for cell proliferation and hepatocyte damage and its high expression was associated with poor survival in HCC patients[37]. Figure 3G shows the immunostaining of PCNA on the liver sections of naive and experimental mice. Negative staining was observed in na?ve (Figure 3G, panel a) and na?ve + nimbolide (Figure 3G, panel b) mice liver whereas, HCC mice liver (Figure 3G, panel c) displayed much higher PCNA-positive nuclei, while treatment with nimbolide (Figure 3G, panel d) or doxorubicin (Figure 3G, panel e) to HCC mice showed reduced PCNA-positive nuclei. Quantification of PCNA positive nuclei in the experimental group was represented in Figure 3H.

    Table 1 Mean tumor volume and tumor growth inhibition (%) in the experimental mice

    Table 2 Mitotic index in the na?ve and experimental mice

    Nimbolide ameliorates hepatic inflammation and oxidative stress in DEN/NMOR induced HCC mice

    Figure 4A-C shows the hepatic NF-κB, TNF-α, and IL-1β protein expressions by western blot in the naive and experimental mice. The hepatic protein expression of NF-κB (P< 0.01), IL-1β (P<0.001), and TNF-α (P< 0.01) were increased in HCC mice compared to naive mice. Nimbolide or doxorubicin treatment to HCC mice showed decreased NF-κB (P< 0.05), IL-1β (P< 0.05), and TNF-α (P< 0.05) protein expressions compared to HCC mice alone. Figure 4D shows immunostaining of 4HNE on the liver sections of naive and experimental mice. Naive (Figure 4D, panel a) and na?ve + nimbolide (Figure 4D, panel b) mice liver showed negative reactivity to 4HNE while 4HNE expression has increased in HCC mice liver (Figure 4D, panel c). Nimbolide (Figure 4D, panel d) or doxorubicin (Figure 4D, panel e) treatment to HCC mice showed reduced hepatic 4HNE nuclear positivity compared to HCC mice alone. Moreover, 4HNE positive nuclei quantification was done and represented in Figure 4E.

    Nimbolide treatment attenuates hepatic ZONAB and cell cycle markers proteins expression in DEN/NMOR induced HCC mice

    Figure 2 Nimbolide inhibits diethylnitrosamine and N-nitrosomorpholine induced hepatocarcinogenesis. A: Macroscopic images of mice liver from na?ve and experimental groups; B: Maximum tumor diameter in na?ve and experimental groups; C: Tumor burden in na?ve and experimental groups; D: Representative images of hematoxylin and eosin stained liver sections from naive and experimental groups (200 × magnification). Scale bar: 200 μm; all the data are expressed as mean ± SEM (n = 6-7). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. dP < 0.05 compared to hepatocellular carcinoma group. HCC: Hepatocellular carcinoma.

    Figure 5A shows the hepatic ZONAB protein expression by western blot in naive and experimental mice. The hepatic ZONAB protein expression was higher (P< 0.0001) in HCC mice compared to naive mice while treatment with nimbolide (P< 0.001) or doxorubicin (P< 0.01) to HCC mice showed reduced ZONAB protein expression compared to HCC mice alone. Figure 5B and C shows the cell cycle markers CDK4 and CyclinD1 protein expressions by western blot in naive and experimental mice. The hepatic CDK4 (P< 0.01) and CyclinD1 (P< 0.001) protein expressions were increased in HCC mice compared to naive mice. Treatment with nimbolide (P< 0.05) or doxorubicin (P< 0.05) to HCC mice showed decreased CDK4 and cyclinD1 protein expression compared to HCC mice alone.

    Nimbolide treatment restores hepatic tight junction protein expressions in DEN/NMOR induced HCC mice

    Figure 6A shows the hepatic occludin protein expression by western blot in naive and experimental mice. The hepatic occludin protein expression was down-regulated (P< 0.01) in HCC mice compared to naive mice while treatment with nimbolide (P< 0.05) or doxorubicin (P< 0.05) to HCC mice, occludin protein expression was up-regulated compared to HCC mice alone. Figure 6B shows the hepatic ZO-1 protein expression by western blot in naive and experimental mice. Moreover, hepatic ZO-1 protein expression was reduced (P< 0.01) in HCC mice compared to naive mice. Nimbolide (P< 0.05) or doxorubicin (P< 0.05) treatment to HCC mice showed significantly increased ZO-1 protein expression when compared to lone HCC.

    Nimbolide has a higher binding affinity towards ZO-1, NF-κB, and TNF-α proteins

    Figure 3 Effect of nimbolide on liver function parameters and tumor and cell proliferation markers in diethylnitrosamine and Nnitrosomorpholine induced hepatocellular carcinoma mice. A: Plasma aspartate aminotransferase level in na?ve and experimental groups; B: Plasma alanine aminotransferase level in na?ve and experimental groups; C: Plasma alkaline phosphatase level in na?ve and experimental groups; D: Plasma alphafetoprotein level in na?ve and experimental groups; E: Representative images of glypican-3 immunostaining of mice liver from naive and experimental groups (200 × magnification); F: Quantification of glypican-3 positive cells in experimental groups by counting five 400 × fields of each liver section; G: Representative images of proliferating hepatocytes by proliferating cell nuclear antigen (PCNA) immunostaining of mice liver from naive and experimental groups (200 × magnification); H: Quantification of PCNA positive nuclei in experimental groups by counting five 400 × fields of each liver section. Scale bar: 200 μm; all the data are expressed as mean ± SEM (n = 3-6). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. cP < 0.0001 compared to na?ve group; dP < 0.05, eP < 0.01 compared to hepatocellular carcinoma group. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; PCNA: Proliferating cell nuclear antigen; HPF: High-power fields; HCC: Hepatocellular carcinoma.

    The 2D structure of nimbolide is represented in Supplementary Figure 3. The 3D structure and ligand binding cavity of ZO-1, NF-κB, and TNF-α was shown in Supplementary Figure 4A-F. Docked complexes of nimbolide and ZO-1 protein showed nimbolide formed hydrogen bonds with amino acid residues Arg 757, Lys 760, Asn 764, Asn 765 and hydrophobic interaction with amino acid residues Ala 623, Pro 710, Lys 760, Leu 761 towards predicted ligand-binding cavity of ZO-1 with a glide score of -9.28 kcal/moL which indicates nimbolide has a strong binding affinity and modulatory effect on ZO-1 protein (Figure 7A-C and Table 3). Molecular docking also revealed nimbolide formed hydrogen bonds with amino acid residues Lys 28, Arg 33, Ser 45 and hydrophobic interaction with amino acid residues Arg 33, Arg 35, Pro 47 towards predicted ligand-binding cavity of NF-κB protein with a glide score of -7.62 kcal/moL suggesting nimbolide has a modulatory effect on NF-κB protein (Figure 7DF and Table 3). Besides, nimbolide also formed hydrogen bonds with amino acid residues Lys 98, Tyr 119 and hydrophobic interaction with amino acid residues Ala 96, Pro 117, Ile 118, Tyr 119 towards predicted ligand-binding cavity of TNF-α protein with a glide score of -8.84 kcal/moL indicating nimbolide has a strong binding and modulatory effect on TNF-α protein (Figure 7G-I and Table 3).

    DISCUSSION

    Our study showed for the first time that nimbolide treatment to DEN and NMOR induced HCC mice exhibits anticancer effect as evidenced by decreased plasma AFP levels and hepatic glypican-3 expression, inhibition of cell cycle progression (ZONAB, CDK4, and cyclinD1), and amelioration of inflammation and oxidative stress. Nimbolide treatment also reduced tumor size, tumor burden, and pathological grade in HCC mice. The other major finding of the current study is increased TJ proteins such as ZO-1 and occludin following treatment with nimbolide to HCC mice. Further, the molecular docking study revealed that nimbolide formed several hydrogen bonds and hydrophobic interactions with amino acid residues of ligand binding cavity ofZO-1, NF-κB, and TNF-α, showing higher binding affinity as observed by high glide score between the docked complexes.

    Table 3 Binding affinity and interaction of nimbolide with different amino-acid residues of zonula occludens 1, nuclear factor of kappa light polypeptide gene enhancer in B-cells and tumor necrosis factor alpha proteins. Binding affinity is represented as Glide score (kcal/moL)

    Doxorubicin is a standard anticancer drug that was also administered to HCC mice to compare the effectiveness of nimbolide. Our results revealed that almost 52.08% of tumor growth was inhibited by nimbolide, whereas doxorubicin inhibited 54.45% tumor growth in HCC mice. Additionally, reduction in liver coefficient, tumor diameter, tumor burden, and tumor volume in HCC mice by nimbolide treatment was also comparable with the standard anticancer drug doxorubicin.

    A key finding of this study was that nimbolide treatment improved hepatic TJ protein (ZO-1 and occludin) expression in HCC mice. Our previous human study showed evidence that decreased hepatic ZO-1 expression was positively correlated with disease severity in HCC patients[20]. Moreover, occludin was also found to be decreased in HCC patients[38]. Of note, our previous study also showed evidence that cirrhotic mice brain exhibited significantly decreased ZO-1, occludin, and claudin-5 protein expression, which were associated with increased inflammation observed in cirrhotic mice[39,40]. The TJ protein ZO-1 has been reported to be involved in cell proliferation[12]. ZO-1 knock-down in mice showing embryonically lethal and was associated with defective angiogenesis of the yolk sac and impaired apoptosis of the embryonic cells[41]. Besides, the deletion of ZO-1 showed increased cell proliferation and neoplastic changes which suggests ZO-1 may have a tumor suppressor role[13]. In this context, lycopene (carotenoid) administration inhibited human cutaneous squamous cell carcinoma (cSCC) cell proliferation by up-regulating ZO-1 expression[42]. Moreover, earlier studies have suggested that ZO-1 regulates cell proliferation by binding to ZONAB, a Y-box transcription factor that has DNA binding element inverted CCAAT box, whose nuclear accumulation leads to transcription of cell cycle related genes such as CDK4, Cyclin D1, and PCNA[14,15]. This was supported by the fact that, in a sparse culture where the proliferation rate is high, the cellular ZONAB expression is high and the ZO-1 expression is low. By contrast, the ZONAB expression is down-regulated and ZO-1 expression is up-regulated in the confluent quiescent monolayer cells[43]. Knock-down of ZO-1 or overexpression of ZONAB resulted in increased proliferation of retinal pigment epithelial cells and induced epithelial to mesenchymal transition phenotype in mice[44]. In the present study, we found increased hepatic protein expression of ZONAB and its transcriptionally regulated cell cycle mediators such as CDK4, cyclinD1, and PCNA expressions in HCC mice, which were decreased following nimbolide treatment. Furthermore, we noted a reciprocal relationship between the protein expression pattern of ZO-1 and ZONAB in HCC mice which was reversed by nimbolide treatment. Thus, our study demonstrated for the first time that ZO-1/ZONAB pathway plays a crucial role in the pathogenesis of HCC by regulating cell cycle progression. Moreover, we also identified that nimbolide interacts with the ligand-binding cavity of ZO-1, forming hydrogen bonds and hydrophobic interaction with amino acids which may have a modulatory effect.

    Figure 4 Nimbolide ameliorates hepatic inflammation and oxidative stress in diethylnitrosamine and N-nitrosomorpholine hepatocellular carcinoma mice. A-C: Hepatic protein expression levels of nuclear factor of kappa light polypeptide gene enhancer in B-cells, interleukin 1 beta and tumor necrosis factor alpha by western blot in naive and experimental groups; D: Representative images of 4-Hydroxynonenal (4HNE) immunostaining of mice liver from naive and experimental groups (200 × magnification); E: Quantification of 4HNE positive nuclei in experimental groups by counting five 400 × fields of each liver section. Scale bar: 200 μm; all the data are expressed as mean ± SEM (n = 3). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. aP < 0.01, bP < 0.001 compared to na?ve group; dP < 0.05, eP < 0.01 compared to hepatocellular carcinoma group. NF-κB: Nuclear factor of kappa light polypeptide gene enhancer in B-cells; IL-1β: Interleukin 1 beta; TNF-α: Tumor necrosis factor alpha; 4HNE: 4-Hydroxynonenal; HCC: Hepatocellular carcinoma.

    Another finding in our study is that nimbolide could regulate cell cycle progression in DEN and NMOR induced HCC in mice. Cell cycle is a major event for cell proliferation and an uncontrolled tumor cell proliferation is responsible for HCC progression[45,46]. CDK4 and cyclinD1 are important mediators of cell cycle progression which are found to be overexpressed and associated with poor prognosis in HCC patients[45,46]. In the presence of extracellular stimuli such as cytokines (TNF-α), the active complex is formed by CDK4/CyclinD1 which phosphorylates retinoblastoma protein (pRb), and promotes the transition of the cell cycle from G1 to S phase through the restriction (R) checkpoint. The pRb induces gene expression necessary for DNA replication such as PCNA during S phase[47]. A previous study has shown that nimbolide regulates cell cycle progression in both cell lines and animal models[48]. In glioblastoma, nimbolide inhibited CDK4/CDK6 kinase activity and arrested cell cycle at the G1 phase[49]. Priyadarsiniet al[50]reported that in HeLa cells nimbolide treatment inhibited major cell cycle regulatory proteins such as cyclin D1, cyclin B, and PCNA and restricted cell cycle at G0/G1 phase[50]. Concurrent with the above studies, we also observed that nimbolide treatment reduces CDK4 and Cyclin D1 protein expression in HCC mice. Therefore, we speculate that nimbolide could inhibit cell proliferation by preventing cell cycle progression from G1 to S phase and prevents HCC pathogenesis.

    In the current study, we found nimbolide might dampen the inflammation through NF-κB pathway in HCC mice. Inflammation has a wide impact on the pathogenesis of cancer development starting from initiation to progression and metastasis. 70% of HCC develops in cirrhotic patients on the background of inflammation[1]. Activation of the NF-κB pathway plays a critical role in inflammation-induced cancer by affecting cell proliferation, apoptosis, angiogenesis, and metastasis[2]. Stimulation of hepatic kupffer cells during chronic inflammation releases proinflammatory cytokines such as TNF-α and IL-1βviathe NF-κB pathway which is known to regulate cell proliferation, survival, and inhibition of apoptosis[2]. In this study, we found increased hepatic protein expression of NF-κB and its downstream mediator proinflammatory cytokines TNF-α and IL-1β in HCC mice, indicating the hyperinflammatory state of hepatic tissue. A previous study indicated that nimbolide administration inhibits NF-κB signaling and proinflammatory cytokines in both cell lines and animal models[48]. In line with this evidence, Kavithaet al[51]reported that nimbolide exerts anticancer effects in HepG2 cells by inhibiting NF-κB signaling and its downstream mediator Wnt/βcatenin pathway[51]. Similarly, Guptaet al[52]reported that nimbolide treatment inhibited xenograft progression in colorectal cancer by targeting the NF-κB pathway and by suppressing pro-inflammatory microenvironment[52]. Concomitant with the above results we also proved that nimbolide treatment attenuated the protein expression of NF-κB, TNF-α, and IL-1β in HCC mice. Moreover, molecular docking study revealed that nimbolide formed hydrogen bonds and hydrophobic interaction with amino acid residues of the ligand binding cavity of NF-κB and TNF-α. These results suggest that nimbolide ameliorated inflammation and suppressed NF-κB signaling in DEN and NMOR induced HCC mice. Therefore it is postulated that nimbolide might regulate cell proliferation by targeting the NF-κB signaling pathway which is considered as a central pathway linking inflammation and cancer[2]. The proposed mechanism of action by which nimbolide exerts its therapeutic effects in HCC mice is depicted in Figure 8.

    DEN is known to induce HCC by generating reactive oxygen species (ROS) which causes oxidative stress in the cell leading to oxidative DNA damage, membrane lipid peroxidation, and mitochondrial damage favoring cell survival and proliferation[53]. 4HNE, a potent and stable by-product of lipid peroxidation, is considered as a marker of oxidative stress, and can independently form DNA adducts, and causes mutation and genetic instability, thus favoring hepatocarcinogenesis[54]. In the current study, we found increased nuclear 4HNE protein expression in HCC mice liver while nimbolide treatment to HCC mice significantly reduced hepatic 4HNE protein expression. This suggests that nimbolide could protect ROS induced oxidative damage and lipid peroxidation in HCC. In this context, Alshammariet al[29]reported that nimbolide treatment abrogates oxidative stress and promotes antioxidants capacity in the primary hepatocytes[29]. Similarly, another study in DMBA induced oral cancer showed that nimbolide inhibited oxidative stress-induced DNA damage by improving antioxidant enzymes[30]. Thus, collectively our results indicate that nimbolide has a potent antioxidant activity and abrogates oxidative stress by quenching free radicals and might restore cellular redox balance thereby attenuating the progression of carcinogenesis. Our study has some limitations that we did not study the nimbolide effects in ZO-1 or ZONAB conditional knock-out mice to prove the exact mechanism of HCC regulation. Indeed, our future experimental approach would delineate this eitherin vivoor in vitro. Moreover, with data obtained in this work, it is not possible to establish the mechanisms involved in the anticancer effect of nimbolide. The study show different mechanisms that occur at the same time than the anticancer effect but a direct relationship between them has not been showed. The efficacy of doxorubicin is very limited in the treatment of human HCC so a limited effect of nimbolide could be also expected.

    Figure 5 Nimbolide treatment attenuates hepatic zonula occludens 1 associated nucleic acid binding protein and cell cycle markers proteins expression in diethylnitrosamine and N-nitrosomorpholine induced hepatocellular carcinoma mice. A: Hepatic protein expression levels of zonula occludens 1 associated nucleic acid binding protein by western blot in naive and experimental groups; B: Hepatic protein expression levels of cyclin dependent kinase 4 by western blot in naive and experimental groups; C: Hepatic protein expression levels of CyclinD1 by western blot in naive and experimental groups. All the data are expressed as mean ± SEM (n = 3). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. aP < 0.01, bP < 0.001, cP < 0.0001 compared to na?ve group; dP < 0.05, eP < 0.01, fP < 0.001 compared to HCC group. ZONAB: Zonula occludens 1 associated nucleic acid binding protein; CDK4: Cyclin dependent kinase; HCC: Hepatocellular carcinoma.

    CONCLUSION

    In conclusion, the results of our study showed evidence in HCC mice that nimbolide treatment suppresses tumor growth and cell cycle progression, and ameliorates inflammation and oxidative stress. Importantly, nimbolide treatment restored hepatic TJ proteins expression and regulates ZO-1/ZONAB pathway in HCC. Our study also demonstrated that the anticancer efficiency of nimbolide was comparable with standard anticancer drug doxorubicin in a preclinical model of HCC. Treatment with natural bioactive compounds, therefore, represents promising chemoprevention agents with minimal side effects, and thus nimbolide could be used as a novel potential candidate drug against HCC progression. Indeed, further molecular and population-based studies are warranted.

    Figure 6 Nimbolide treatment restores hepatic tight junction protein expression in diethylnitrosamine and N-nitrosomorpholine induced hepatocellular carcinoma mice. A and B: Hepatic protein expression levels of occludin and zonula occludens 1 by western blot in naive and experimental groups. All the data are expressed as mean ± SEM (n = 3). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. aP < 0.01 compared to na?ve group; dP<0.05 compared to hepatocellular carcinoma group. ZO-1: Zonula occludens 1; HCC: Hepatocellular carcinoma.

    Figure 7 Molecular docking analysis of nimbolide with zonula occludens 1, nuclear factor of kappa light polypeptide gene enhancer in Bcells and tumor necrosis factor alpha. A and B: Representation of nimbolide and zonula occludens 1 (ZO-1) docking complex; C: Interaction of nimbolide with amino acid residues of ZO-1; D and E: Representation of nimbolide and nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB) docking complex; F: Interaction of nimbolide with amino acid residues of NF-κB; G and H: Representation of nimbolide and tumor necrosis factor alpha (TNF-α) docking complex; I: Interaction of nimbolide with amino acid residues of TNF-α.

    Figure 8 Schematic representation of the mechanism of action of nimbolide in diethylnitrosamine and N-nitrosomorpholine induced hepatocellular carcinoma mice. Nimbolide treatment inhibits tumor growth in diethylnitrosamine and N-nitrosomorpholine induced Hepatocellular carcinoma (HCC) mice by targeting tight junctions (TJs) proteins [Zonula occludens-1 (ZO-1) and Occludin]. Nimbolide mediated up-regulation of ZO-1 represses the transcriptional activity of ZO-1 associated nucleic acid binding protein at a junctional site preventing its nuclear accumulation and thus preventing the induction of cell cycle related genes cyclin dependent kinase 4, cyclinD1 and proliferating cell nuclear antigen. Nimbolide treatment also restores barrier integrity by up-regulation TJs proteins which prevent translocation of growth factors and nutrients necessary for cell growth from apical to the basolateral domain. Further, nimbolide also targets the nuclear factor of kappa light polypeptide gene enhancer in B-cells pathway ameliorating inflammation in HCC mice. ZO-1: Zonula occludens 1; ZONAB: ZO-1 associated nucleic acid binding protein; CDK4: Cyclin dependent kinase; PCNA: Proliferating cell nuclear antigen; NF-κB: Nuclear factor of kappa light polypeptide gene enhancer in B-cells; IL-1β: Interleukin 1 beta; TNF-α: Tumor necrosis factor alpha; HCC: Hepatocellular carcinoma.

    ARTICLE HIGHLIGHTS

    Research background

    Worldwide, hepatocellular carcinoma (HCC) is a prevalent lethal disease exhibiting the highest cancer mortality rate with limited chemotherapeutic options. The discovery of a new chemotherapeutic agent is an urgent demand for the treatment of HCC patients.

    Research motivation

    Tight Junction (TJ) proteins have been implicated to regulate various signal transductions in carcinogenesis. Recent evidence has shown that nimbolide possesses anticancer activity in various cancers; however, its specific mechanism in HCC remains elusive.

    Research objectives

    We aimed to study the effect of nimbolide on TJ proteins, cell cycle progression, and hepatic inflammation in an experimental hepatocarcinogenesis mouse model.

    Research methods

    Diethylnitrosamine (DEN) and N-nitrosomorpholine (NMOR) induced mouse model of HCC was performed in the present study. Nimbolide was given orally for four consecutive weeks to DEN/NMOR induced HCC mice from 28thto 32ndweek. At the end of the study period (32ndweek), all the mice were sacrificed, blood and liver samples were collected for various analysis. HCC tumor markers such as alphafetoprotein (AFP) levels and glypican-3 protein expression were analysed. Hepatic TJ proteins, cell cycle, and inflammatory marker protein expressions were evaluated by western blot analysis. Cell proliferation and oxidative stress markers were analyzed by immunohistochemistry. Molecular docking study was performed to confirm the interaction of nimbolide with zonula occludens 1 (ZO-1), nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB) and tumor necrosis factor alpha (TNF-α).

    Research results

    Hepatic tumor size and HCC tumor markers AFP and glypican-3 were reduced following nimbolide treatment. TJ protein (ZO-1 and occludin) expression levels were restored after nimbolide treatment, while ZO-1 associated nucleic acid binding protein expression was attenuated. Additionally, nimbolide treatment also reduced cell proliferation and cell cycle markers. Moreover, nimbolide treatment ameliorated hepatic inflammation and oxidative stress in HCC mice. The binding affinity and modulatory effects of nimbolide with ZO-1, NF-κB, and TNF-α were confirmed by molecular docking analysis.

    Research conclusions

    Nimbolide treatment showed anticancer effects by improving TJ proteins expression, suppressing cell cycle and cell proliferation, and ameliorating inflammation and oxidative stress in DEN and NMOR induced HCC mice.

    Research perspectives

    Nimbolide may be used as a potential chemotherapeutic agent for HCC treatment. Further molecular research and human studies may delineate nimbolide as a candidate drug for HCC treatment.

    ACKNOWLEDGEMENTS

    We thank Dr. Athithan V, PhD, for analyzing molecular docking studies.

    国产精品98久久久久久宅男小说| 一区二区三区精品91| 亚洲精品一区av在线观看| 岛国在线观看网站| √禁漫天堂资源中文www| 两性夫妻黄色片| 久久国产精品男人的天堂亚洲| 国产精品98久久久久久宅男小说| 怎么达到女性高潮| 亚洲人成电影免费在线| 丝袜美腿诱惑在线| 久久精品国产清高在天天线| 亚洲成人久久性| 曰老女人黄片| 老司机深夜福利视频在线观看| 美国免费a级毛片| 亚洲一区二区三区不卡视频| 麻豆成人av在线观看| 欧美一区二区精品小视频在线| 男人舔女人的私密视频| 很黄的视频免费| 日韩欧美一区视频在线观看| 色老头精品视频在线观看| 亚洲情色 制服丝袜| 久久久国产成人免费| 国产精品av久久久久免费| 乱人伦中国视频| 亚洲精品中文字幕在线视频| 国产精品乱码一区二三区的特点 | 亚洲第一欧美日韩一区二区三区| 久久国产乱子伦精品免费另类| 老熟妇乱子伦视频在线观看| 精品国产国语对白av| 精品卡一卡二卡四卡免费| 免费无遮挡裸体视频| 99久久久亚洲精品蜜臀av| 99热只有精品国产| 母亲3免费完整高清在线观看| 欧美人与性动交α欧美精品济南到| 69精品国产乱码久久久| 一区二区三区国产精品乱码| 亚洲人成网站在线播放欧美日韩| avwww免费| 两个人视频免费观看高清| tocl精华| 国产av一区在线观看免费| 老司机在亚洲福利影院| 午夜两性在线视频| 国产不卡一卡二| 麻豆成人av在线观看| 搡老岳熟女国产| 叶爱在线成人免费视频播放| 中出人妻视频一区二区| 欧美日韩精品网址| 久久精品国产清高在天天线| 欧美乱妇无乱码| 最近最新中文字幕大全电影3 | 熟妇人妻久久中文字幕3abv| 99re在线观看精品视频| 男女下面插进去视频免费观看| www国产在线视频色| www.熟女人妻精品国产| 女同久久另类99精品国产91| 欧美在线黄色| 国产精品自产拍在线观看55亚洲| 好男人在线观看高清免费视频 | 亚洲欧美激情综合另类| 亚洲最大成人中文| 国产av一区二区精品久久| 母亲3免费完整高清在线观看| 国产国语露脸激情在线看| 久久久久国产一级毛片高清牌| 一本大道久久a久久精品| 亚洲成人免费电影在线观看| 在线观看免费视频网站a站| 99国产精品一区二区蜜桃av| 久久久精品国产亚洲av高清涩受| 天堂影院成人在线观看| 精品国产亚洲在线| 国产精品久久久久久精品电影 | 给我免费播放毛片高清在线观看| 熟女少妇亚洲综合色aaa.| 欧美 亚洲 国产 日韩一| ponron亚洲| 久热这里只有精品99| 日韩av在线大香蕉| 99久久综合精品五月天人人| 黄色丝袜av网址大全| 黑人巨大精品欧美一区二区mp4| 男女午夜视频在线观看| 色综合站精品国产| 国产成人一区二区三区免费视频网站| 欧美久久黑人一区二区| 好看av亚洲va欧美ⅴa在| 91成人精品电影| 老汉色av国产亚洲站长工具| 亚洲中文av在线| 可以在线观看的亚洲视频| 亚洲精品国产色婷婷电影| 午夜福利影视在线免费观看| 免费av毛片视频| 制服丝袜大香蕉在线| 嫁个100分男人电影在线观看| xxx96com| 亚洲国产高清在线一区二区三 | 欧美色欧美亚洲另类二区 | 亚洲欧美精品综合一区二区三区| 1024香蕉在线观看| 久久久久久久久久久久大奶| 操美女的视频在线观看| 老司机深夜福利视频在线观看| 91字幕亚洲| 国产免费av片在线观看野外av| 亚洲精品久久国产高清桃花| svipshipincom国产片| 午夜日韩欧美国产| 日韩 欧美 亚洲 中文字幕| 黄色视频,在线免费观看| 如日韩欧美国产精品一区二区三区| 脱女人内裤的视频| 亚洲一区二区三区色噜噜| 欧美av亚洲av综合av国产av| a在线观看视频网站| 午夜久久久在线观看| 真人做人爱边吃奶动态| 在线观看免费视频网站a站| 免费看美女性在线毛片视频| 91成年电影在线观看| 国产熟女午夜一区二区三区| 两个人看的免费小视频| 超碰成人久久| 午夜福利,免费看| 日韩av在线大香蕉| 窝窝影院91人妻| 亚洲中文字幕日韩| 久久精品国产清高在天天线| 日本vs欧美在线观看视频| 国产成人免费无遮挡视频| 欧美日本亚洲视频在线播放| 大陆偷拍与自拍| 成人三级做爰电影| 无限看片的www在线观看| 一a级毛片在线观看| 在线观看午夜福利视频| 亚洲精品国产色婷婷电影| 午夜视频精品福利| 90打野战视频偷拍视频| 国产亚洲欧美98| 激情在线观看视频在线高清| 久久精品国产亚洲av香蕉五月| 亚洲av第一区精品v没综合| 久久伊人香网站| 色婷婷久久久亚洲欧美| 成人三级黄色视频| 免费人成视频x8x8入口观看| 性欧美人与动物交配| 咕卡用的链子| 精品久久久久久,| 亚洲国产欧美一区二区综合| 亚洲第一电影网av| 此物有八面人人有两片| 大陆偷拍与自拍| 国产欧美日韩一区二区精品| 看片在线看免费视频| 亚洲国产高清在线一区二区三 | 在线观看免费日韩欧美大片| 激情在线观看视频在线高清| 国产亚洲精品综合一区在线观看 | 久久久久国产精品人妻aⅴ院| av天堂久久9| 久久精品国产综合久久久| 少妇粗大呻吟视频| 男女做爰动态图高潮gif福利片 | 最新在线观看一区二区三区| 久久精品91蜜桃| 久久精品aⅴ一区二区三区四区| 91国产中文字幕| 两个人看的免费小视频| 男男h啪啪无遮挡| 免费少妇av软件| 一夜夜www| 国产欧美日韩综合在线一区二区| 又黄又爽又免费观看的视频| 91麻豆精品激情在线观看国产| 女警被强在线播放| 精品久久久久久久人妻蜜臀av | 夜夜爽天天搞| 国产精品 欧美亚洲| 一边摸一边抽搐一进一出视频| 亚洲视频免费观看视频| 国产熟女午夜一区二区三区| 波多野结衣巨乳人妻| 在线观看一区二区三区| 午夜免费激情av| 久久 成人 亚洲| 久久久久亚洲av毛片大全| 久久精品人人爽人人爽视色| 天堂影院成人在线观看| 午夜视频精品福利| 女生性感内裤真人,穿戴方法视频| 免费在线观看亚洲国产| 不卡av一区二区三区| 亚洲,欧美精品.| 给我免费播放毛片高清在线观看| 91大片在线观看| 亚洲熟女毛片儿| 国产精品久久久久久精品电影 | 制服丝袜大香蕉在线| 两个人看的免费小视频| 国产欧美日韩一区二区三区在线| 免费人成视频x8x8入口观看| 精品一区二区三区av网在线观看| 12—13女人毛片做爰片一| 久久人妻熟女aⅴ| 精品久久蜜臀av无| 看黄色毛片网站| 神马国产精品三级电影在线观看 | 国产精品久久久久久亚洲av鲁大| 久久精品成人免费网站| 最新美女视频免费是黄的| 国产亚洲av高清不卡| 天堂动漫精品| 两人在一起打扑克的视频| 久热爱精品视频在线9| 色综合亚洲欧美另类图片| 一进一出抽搐动态| 久久精品亚洲精品国产色婷小说| 午夜福利高清视频| 这个男人来自地球电影免费观看| 精品一区二区三区av网在线观看| 亚洲片人在线观看| 国产欧美日韩一区二区精品| 啦啦啦观看免费观看视频高清 | 久久中文字幕一级| 欧美一级a爱片免费观看看 | 亚洲欧美激情综合另类| 麻豆久久精品国产亚洲av| 久久久水蜜桃国产精品网| 成人三级做爰电影| 日韩成人在线观看一区二区三区| 最近最新中文字幕大全免费视频| 欧美日本视频| 啦啦啦免费观看视频1| a级毛片在线看网站| 级片在线观看| 中文亚洲av片在线观看爽| 性色av乱码一区二区三区2| 成人三级做爰电影| 韩国精品一区二区三区| 高清黄色对白视频在线免费看| 亚洲色图综合在线观看| 国产在线观看jvid| 色精品久久人妻99蜜桃| 一边摸一边抽搐一进一出视频| 午夜福利欧美成人| 国产97色在线日韩免费| 欧美成人午夜精品| 亚洲精品中文字幕一二三四区| 美女扒开内裤让男人捅视频| 女人被躁到高潮嗷嗷叫费观| 又大又爽又粗| 亚洲av成人一区二区三| 亚洲av成人av| 久久久精品国产亚洲av高清涩受| 亚洲精品在线美女| 黄频高清免费视频| 91在线观看av| 久久婷婷人人爽人人干人人爱 | 变态另类成人亚洲欧美熟女 | 91老司机精品| 此物有八面人人有两片| 别揉我奶头~嗯~啊~动态视频| 在线国产一区二区在线| 亚洲av成人av| 亚洲精品国产一区二区精华液| 久久久久国产精品人妻aⅴ院| 露出奶头的视频| 老司机午夜福利在线观看视频| 伊人久久大香线蕉亚洲五| 精品国产乱码久久久久久男人| 女人精品久久久久毛片| 国产一区二区三区视频了| 欧美日韩中文字幕国产精品一区二区三区 | 日韩大码丰满熟妇| 看黄色毛片网站| 国产精品影院久久| 给我免费播放毛片高清在线观看| 亚洲欧洲精品一区二区精品久久久| 国产精品1区2区在线观看.| 亚洲国产欧美日韩在线播放| 中文字幕人成人乱码亚洲影| 女性生殖器流出的白浆| 男人的好看免费观看在线视频 | 嫩草影视91久久| 无遮挡黄片免费观看| 国产一卡二卡三卡精品| 亚洲五月天丁香| 日韩欧美在线二视频| 在线观看舔阴道视频| 精品久久久久久久久久免费视频| 中文字幕av电影在线播放| 国产精品亚洲美女久久久| ponron亚洲| 在线永久观看黄色视频| 亚洲精品国产精品久久久不卡| 亚洲性夜色夜夜综合| bbb黄色大片| 精品久久蜜臀av无| 最近最新中文字幕大全电影3 | 国产亚洲av嫩草精品影院| 99久久综合精品五月天人人| 亚洲在线自拍视频| 亚洲欧美日韩高清在线视频| 久久人人97超碰香蕉20202| 露出奶头的视频| 午夜久久久在线观看| 亚洲第一av免费看| 别揉我奶头~嗯~啊~动态视频| 中文字幕精品免费在线观看视频| 欧美午夜高清在线| 性少妇av在线| 动漫黄色视频在线观看| 亚洲国产看品久久| tocl精华| 成人av一区二区三区在线看| 欧美色视频一区免费| 曰老女人黄片| 此物有八面人人有两片| 国产极品粉嫩免费观看在线| 欧美日韩精品网址| 免费人成视频x8x8入口观看| 在线国产一区二区在线| 国产精品日韩av在线免费观看 | 动漫黄色视频在线观看| 午夜亚洲福利在线播放| 成人国语在线视频| 国产亚洲精品第一综合不卡| 1024视频免费在线观看| 国产精品99久久99久久久不卡| 国产精品一区二区三区四区久久 | 国产精品亚洲美女久久久| or卡值多少钱| 久久人妻av系列| 一区二区三区高清视频在线| 日韩av在线大香蕉| 成熟少妇高潮喷水视频| 99re在线观看精品视频| 精品无人区乱码1区二区| 大型黄色视频在线免费观看| 嫁个100分男人电影在线观看| 又紧又爽又黄一区二区| 国产伦人伦偷精品视频| 久久香蕉激情| 日韩免费av在线播放| 亚洲aⅴ乱码一区二区在线播放 | 成人三级做爰电影| 亚洲全国av大片| 国产精华一区二区三区| 欧美乱码精品一区二区三区| 精品国产美女av久久久久小说| 成人18禁在线播放| 女人高潮潮喷娇喘18禁视频| 两人在一起打扑克的视频| 一区二区三区激情视频| 色综合站精品国产| 久久热在线av| 成人国产一区最新在线观看| 很黄的视频免费| 久热爱精品视频在线9| 久久天躁狠狠躁夜夜2o2o| 91在线观看av| 久久人妻福利社区极品人妻图片| 怎么达到女性高潮| 波多野结衣av一区二区av| 久久性视频一级片| 欧美最黄视频在线播放免费| 亚洲精品粉嫩美女一区| av天堂久久9| 亚洲,欧美精品.| 久久久久国产一级毛片高清牌| 18禁观看日本| 男人的好看免费观看在线视频 | 久久午夜亚洲精品久久| 亚洲中文字幕一区二区三区有码在线看 | 日韩av在线大香蕉| 国语自产精品视频在线第100页| 久久天堂一区二区三区四区| 黑丝袜美女国产一区| 国产成人系列免费观看| 19禁男女啪啪无遮挡网站| 精品国产一区二区久久| 成年女人毛片免费观看观看9| 女人爽到高潮嗷嗷叫在线视频| 老司机在亚洲福利影院| 免费在线观看完整版高清| 国产色视频综合| 最近最新中文字幕大全电影3 | 国产又色又爽无遮挡免费看| 在线观看日韩欧美| 又黄又爽又免费观看的视频| 亚洲九九香蕉| 夜夜躁狠狠躁天天躁| 丰满的人妻完整版| 亚洲成av人片免费观看| 一进一出抽搐gif免费好疼| 欧美成人一区二区免费高清观看 | 国产精品乱码一区二三区的特点 | 最新美女视频免费是黄的| 午夜免费成人在线视频| 中文字幕色久视频| 日本五十路高清| 欧美黄色淫秽网站| 亚洲 国产 在线| 操美女的视频在线观看| 男人舔女人的私密视频| 女人精品久久久久毛片| www.自偷自拍.com| 在线av久久热| 韩国精品一区二区三区| 久久精品国产99精品国产亚洲性色 | 亚洲一区二区三区不卡视频| 久久天堂一区二区三区四区| 久久青草综合色| 国产精品香港三级国产av潘金莲| 国产av一区在线观看免费| 美女大奶头视频| 亚洲国产中文字幕在线视频| av中文乱码字幕在线| 首页视频小说图片口味搜索| 国产xxxxx性猛交| 国产av一区在线观看免费| 国产成年人精品一区二区| 人人妻,人人澡人人爽秒播| 久久九九热精品免费| 中文字幕精品免费在线观看视频| 中亚洲国语对白在线视频| 亚洲一区中文字幕在线| www.www免费av| 9热在线视频观看99| 亚洲人成电影观看| 97人妻天天添夜夜摸| 午夜免费激情av| 国产精品99久久99久久久不卡| 亚洲五月婷婷丁香| 久久精品91蜜桃| 一级作爱视频免费观看| 一区二区三区高清视频在线| 免费在线观看亚洲国产| av天堂在线播放| 两性夫妻黄色片| 在线观看免费视频日本深夜| 国产三级黄色录像| 91精品国产国语对白视频| 婷婷六月久久综合丁香| 99精品在免费线老司机午夜| 日本精品一区二区三区蜜桃| 久久精品国产综合久久久| 美女高潮到喷水免费观看| 成人永久免费在线观看视频| 极品教师在线免费播放| 欧美日韩精品网址| 亚洲黑人精品在线| 亚洲中文字幕一区二区三区有码在线看 | 国产精品 国内视频| 一本综合久久免费| 日本 欧美在线| 岛国在线观看网站| 成年人黄色毛片网站| 国产精品一区二区精品视频观看| 精品免费久久久久久久清纯| 免费在线观看亚洲国产| 亚洲欧美精品综合久久99| 亚洲欧美日韩另类电影网站| 深夜精品福利| 性少妇av在线| 国产精品98久久久久久宅男小说| 午夜免费观看网址| 欧美乱妇无乱码| 亚洲av片天天在线观看| 色在线成人网| 久久亚洲真实| 一本综合久久免费| 日韩欧美一区视频在线观看| 精品国产乱子伦一区二区三区| 天天躁夜夜躁狠狠躁躁| 嫁个100分男人电影在线观看| 国产精品98久久久久久宅男小说| videosex国产| 亚洲 欧美一区二区三区| 国产亚洲精品第一综合不卡| 在线天堂中文资源库| 在线观看日韩欧美| 欧美性长视频在线观看| 久久婷婷人人爽人人干人人爱 | 精品无人区乱码1区二区| 日韩精品中文字幕看吧| 久久人妻福利社区极品人妻图片| 91精品国产国语对白视频| 国产黄a三级三级三级人| 国产亚洲欧美98| 久久午夜综合久久蜜桃| 亚洲精品在线美女| 一本久久中文字幕| 亚洲少妇的诱惑av| 伦理电影免费视频| 欧美老熟妇乱子伦牲交| 亚洲国产欧美网| 国产精品爽爽va在线观看网站 | 叶爱在线成人免费视频播放| 国产精品免费视频内射| 欧美日韩一级在线毛片| 纯流量卡能插随身wifi吗| www国产在线视频色| 久久精品国产清高在天天线| 午夜久久久久精精品| АⅤ资源中文在线天堂| 又黄又爽又免费观看的视频| 成年人黄色毛片网站| 少妇粗大呻吟视频| 色av中文字幕| 老汉色av国产亚洲站长工具| 亚洲国产欧美网| 中国美女看黄片| 亚洲av成人不卡在线观看播放网| 午夜老司机福利片| 国产高清激情床上av| 欧美中文综合在线视频| 久久久国产精品麻豆| 亚洲av片天天在线观看| 丝袜人妻中文字幕| 国产精品98久久久久久宅男小说| 黄色片一级片一级黄色片| 亚洲av成人不卡在线观看播放网| 国产av一区在线观看免费| 国产91精品成人一区二区三区| 欧美日本视频| 性色av乱码一区二区三区2| 欧美日韩黄片免| 99香蕉大伊视频| 久久国产精品男人的天堂亚洲| 亚洲av电影不卡..在线观看| 女生性感内裤真人,穿戴方法视频| 91精品国产国语对白视频| av超薄肉色丝袜交足视频| 国产精品一区二区精品视频观看| 午夜亚洲福利在线播放| 亚洲一区中文字幕在线| av在线天堂中文字幕| 黄网站色视频无遮挡免费观看| 中国美女看黄片| 亚洲精品一区av在线观看| 国产成人欧美在线观看| 男女床上黄色一级片免费看| 夜夜躁狠狠躁天天躁| 国产高清有码在线观看视频 | a在线观看视频网站| 亚洲欧美日韩另类电影网站| 亚洲欧美激情综合另类| 欧美在线黄色| 窝窝影院91人妻| av在线天堂中文字幕| 亚洲精品在线美女| 亚洲人成电影免费在线| 少妇被粗大的猛进出69影院| 黄片播放在线免费| 国产成人精品久久二区二区91| 曰老女人黄片| x7x7x7水蜜桃| 久久久国产欧美日韩av| 精品国内亚洲2022精品成人| 国产精品二区激情视频| 曰老女人黄片| 色播亚洲综合网| 国产精品亚洲一级av第二区| 亚洲免费av在线视频| 亚洲片人在线观看| 在线国产一区二区在线| а√天堂www在线а√下载| 午夜福利高清视频| 国产区一区二久久| 美女高潮喷水抽搐中文字幕| 欧美最黄视频在线播放免费| 久久精品91无色码中文字幕| 侵犯人妻中文字幕一二三四区| 日韩一卡2卡3卡4卡2021年| 国产野战对白在线观看| 脱女人内裤的视频| 久久久久久久久久久久大奶| 最好的美女福利视频网| 免费观看精品视频网站| 色精品久久人妻99蜜桃| 波多野结衣av一区二区av| 99精品在免费线老司机午夜| 久久婷婷人人爽人人干人人爱 | 亚洲国产日韩欧美精品在线观看 | 国产精品自产拍在线观看55亚洲| 中文亚洲av片在线观看爽| 久久久国产成人精品二区| 国产一区二区在线av高清观看| 又紧又爽又黄一区二区| 老司机午夜福利在线观看视频| 国产三级黄色录像| 亚洲中文字幕日韩| 亚洲av电影不卡..在线观看| 嫩草影院精品99| 久久久久久免费高清国产稀缺| 免费久久久久久久精品成人欧美视频| 嫩草影院精品99| 亚洲国产欧美日韩在线播放| www.熟女人妻精品国产| 男女之事视频高清在线观看| 久久人人97超碰香蕉20202| 九色国产91popny在线| 日韩av在线大香蕉| 国产亚洲精品第一综合不卡|